Letybo Earns FDA Approval, Hugel Expands Its Global Aesthetic Market Leadership
XTalks
JUNE 17, 2024
Hugel, a Korean medical aesthetics company, recently announced that it has received marketing approval from the US Food and Drug Administration (FDA) for its botulinum toxin, Letybo (letibotulinumtoxinA-wlbg), for the treatment of glabellar lines.
Let's personalize your content